XENE Company Profile and Key Details

Q: Who are the executives of XENE?

Ms. Sherry AulinChief Financial OfficerMs. Shelley McCloskey B.A.Executive Vice President of HRMs. Sheila M. Grant M.B.A., M.Sc., MBAExecutive Vice President of R&D OperationsMr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBAPres, Chief Executive Officer & DirectorDr. Robin P. Sherrington Ph.D.Executive Vice President of Strategy & InnovationDr. James R. Empfield Ph.D.Executive Vice President of Drug DiscoveryMs. Jodi Regts M.B.A., B.A., MBAVice President of Corporation Affairs & Investor RelationsDr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.Chief Commercial OfficerMs. Andrea DiFabio J.D.Chief Legal Officer & Corporation Sec.Dr. Christopher John Kenney M.D.Chief Medical OfficerMr. Ian C. Mortimer C.M.A., C.P.A., CMA, CPA, M.B.A., MBAPres, Chief Executive Officer & Director

NASDAQ : XENE

Xenon Pharmaceuticals

$42.55

-0.68-1.57%

At Close 4:00 PM

59.27

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Xenon Pharmaceuticals Inc. (XENE) stock declined over -1.57%, trading at $42.55 on NASDAQ, down from the previous close of $43.23. The stock opened at $42.57, fluctuating between $42.36 and $44.00 in the recent session.

Stock Snapshot

43.23

Prev. Close

3.29B

Market Cap

42.36

Day Low

-10.94

P/E Ratio

-3.89

EPS (TTM)

-2.13

Cash Flow per Share

42.57

Open

77.28M

Number of Shares

Day High

92.85%

Free Float in %

13.26

Book Value

1.28M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 02, 2026	42.57	44.00	42.26	42.55	1.29M
Feb 27, 2026	45.40	46.99	42.01	43.23	1.66M
Feb 26, 2026	44.58	45.01	43.76	44.92	700.71K
Feb 25, 2026	45.00	45.41	43.57	44.58	615.64K
Feb 24, 2026	43.35	44.82	43.14	44.79	942.55K
Feb 23, 2026	42.06	43.40	42.06	42.72	701.41K
Feb 20, 2026	43.00	43.18	41.44	42.23	725.33K
Feb 19, 2026	42.52	43.36	42.13	43.08	646.78K
Feb 18, 2026	41.68	42.97	41.65	42.51	800.7K
Feb 17, 2026	41.32	42.31	40.86	41.66	1.08M
Feb 13, 2026	41.82	42.90	41.36	41.48	763.83K
Feb 12, 2026	42.89	43.00	41.50	41.62	718.34K
Feb 11, 2026	42.66	43.12	40.74	42.76	900.04K
Feb 10, 2026	43.00	43.67	42.13	42.63	862.14K
Feb 09, 2026	41.48	42.99	40.93	42.43	748.12K
Feb 06, 2026	41.09	41.75	40.80	41.38	611.41K
Feb 05, 2026	41.11	41.93	40.30	40.39	542.36K
Feb 04, 2026	42.21	42.51	40.72	41.15	684.33K
Feb 03, 2026	41.85	42.51	41.26	42.12	841.01K
Feb 02, 2026	41.01	42.14	40.71	41.45	649.55K

Contact Details

Burnaby, BC V5G 4W8

Canada

https://www.xenon-pharma.com 160 448 43300

About Company

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Stock Peers

REGN

9.14+1.17%

Regeneron Pharmaceuticals, Inc.$790.81 ARGX

-10.16-1.32%

argenx SE$756.76 UTHR

9.92+1.97%

United Therapeutics Corporation$513.82 VRTX

-10.8-2.17%

Vertex Pharmaceuticals Incorporated$486.03 MDGL

3.62+0.84%

Madrigal Pharmaceuticals, Inc.$435.62 PRAX

-6.16-1.83%

Praxis Precision Medicines, Inc.$330.59 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-7.85-2.36%

Alnylam Pharmaceuticals, Inc.$325.07 KRYS

-16.83-6.11%

Krystal Biotech, Inc.$258.81 ASND

8.59+3.68%

Ascendis Pharma A/S$242.09

Frequently Asked Questions

What is the current Xenon Pharmaceuticals Inc. (XENE) stock price?

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) stock price is $42.55 in the last trading session. During the trading session, XENE stock reached the peak price of $44.00 while $42.36 was the lowest point it dropped to. The percentage change in XENE stock occurred in the recent session was -1.57% while the dollar amount for the price change in XENE stock was - $0.68.

XENE's industry and sector of operation?

The NASDAQ listed XENE is part of Biotechnology industry that operates in the broader Healthcare sector. Xenon Pharmaceuticals Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of XENE?

Ms. Sherry Aulin
Chief Financial Officer
Ms. Shelley McCloskey B.A.
Executive Vice President of HR
Ms. Sheila M. Grant M.B.A., M.Sc., MBA
Executive Vice President of R&D Operations
Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA
Pres, Chief Executive Officer & Director
Dr. Robin P. Sherrington Ph.D.
Executive Vice President of Strategy & Innovation
Dr. James R. Empfield Ph.D.
Executive Vice President of Drug Discovery
Ms. Jodi Regts M.B.A., B.A., MBA
Vice President of Corporation Affairs & Investor Relations
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.
Chief Commercial Officer
Ms. Andrea DiFabio J.D.
Chief Legal Officer & Corporation Sec.
Dr. Christopher John Kenney M.D.
Chief Medical Officer
Mr. Ian C. Mortimer C.M.A., C.P.A., CMA, CPA, M.B.A., MBA
Pres, Chief Executive Officer & Director

How XENE did perform over past 52-week?

XENE's closing price is 59.12% higher than its 52-week low of $26.74 where as its distance from 52-week high of $46.99 is -9.45%.

How many employees does XENE have?

Number of XENE employees currently stands at 316.

Link for XENE official website?

Official Website of XENE is: https://www.xenon-pharma.com

How do I contact XENE?

XENE could be contacted at phone 160 448 43300 and can also be accessed through its website. XENE operates from 3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

How many shares of XENE are traded daily?

XENE stock volume for the day was 1.28M shares. The average number of XENE shares traded daily for last 3 months was 877K.

What is the market cap of XENE currently?

The market value of XENE currently stands at $3.29B with its latest stock price at $42.55 and 77.28M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	316
Beta	0.96
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	316
Beta	0.96
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

XENE Company Profile and Key Details

Xenon Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Earnings & Analyst Outlook

Key Takeaways

Price Forecast & Outlook

Valuation Metrics